MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma

Immune checkpoint blockade (ICB) has demonstrated an impressive outcome in patients with metastatic melanoma, yet, durable complete response; even with Ipilimumab/Nivolumab combo are under 30%. Primary and acquired resistance in response to ICB is commonly due to a tumor immune escape mechanism dict...

Descripción completa

Detalles Bibliográficos
Autores principales: de Azevedo, Ricardo A., Shoshan, Einav, Whang, Shanzhi, Markel, Gal, Jaiswal, Ashvin R., Liu, Arthur, Curran, Michael A., Travassos, Luiz R., Bar-Eli, Menashe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733907/
https://www.ncbi.nlm.nih.gov/pubmed/33344042
http://dx.doi.org/10.1080/2162402X.2020.1846915

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733907/
https://www.ncbi.nlm.nih.gov/pubmed/33344042
http://dx.doi.org/10.1080/2162402X.2020.1846915

Ejemplares similares